
Excited to now be able to offer point-of-care ultrasound for the #IBDpatients of @ChildrensLA. We now can offer close non-invasive monitoring options for disease activity. Took a while, but here it is!

Pediatric gastroenterologist with focus on IBD, intestinal ultrasound and precision medicine @ChildrensLA. Daughter, wife, 🇭🇹 descent. Tweets are my own.

Excited to now be able to offer point-of-care ultrasound for the #IBDpatients of @ChildrensLA. We now can offer close non-invasive monitoring options for disease activity. Took a while, but here it is!

If you are subscribed to ibd-eii.com you will receive after a long time an email! 🚀 Big news! ibd-eii.com has been reinvented I’ve transformed the platform into a powerful, intuitive content database to make finding IBD drugs, trials, and evidence easier What’s new? • A smart, searchable database 🔍 • Easier organization and classification method • 15+ new clinical trial summaries📚 • Updated cheat sheets 🧠 👇 #IBD #CrohnsDisease #UlcerativeColitis #Gastroenterology #MedEd

Hands on practice with IUS at #CCCongress2026. Giving providers the tools they need to take back to their IBD patients and bring IUS to the bedside.

TLDR on cannabinoids for #IBD ⭐️may improve symptoms (pain/diarrhea) ⭐️BUT no effect on disease activity ⭐️understand the WHY behind using cannabinoids and HOW we can optimize therapy. ⭐️Increase risk of hospitalization and surgery with use Pearls from @ibdgijami #AIBD2025

New ESPGHAN/ECCO ASUC Consensus take-aways: ➡️VTE prophylaxis in all hospitalized pts ➡️IFX 10mg/kg-use TDM to guide dosing ➡️PJP prophylaxis in appropriate scenario: triple immunosuppression, double immunosuppression (1 CNI), steroid + low lymphocytes or JAKi #aibd2025

Shameless plug of this abstract featuring @Evinature_ CurQD in #PediatricIBD showing improvement in symptoms, calprotectin and even #IUS presented at #CCCongress2024! #AIBD2025

From the complementary medicine clinical breakout session at #AIBD2025, high usage amongst our patients. Good incentive for #IBD docs to learn more about the risk and benefits! @AIBDNetwork

@MaiaKayalMD excellent talk on Pouchitis at #AIBD2025 @AIBDNetwork 🎯Targets in the management of pouchitis - less stringent - aim for ⬆️ QofL, clinical remission, and endo improvement 🍎🥔🍠Bonus image on diet modifications suggested for pouchitis! @GimdGold

🚨 Attention young faculty & trainees! I asked these two #PedsGI @ShermanPrize success stories for one piece of advice on making meaningful progress for patients with #IBD: Scott emphasized investing in #trainees to create a broad, lasting impact and legacy, while Mike highlighted finding #knowledgegaps—often by looking to what other fields are doing that IBD isn’t—and focusing efforts there. That’s a pretty great roadmap. 💡🧠 #PedsGI #ShermanPrize #AIBD2025


#AIBD2025 is a great opportunity to meet old and new friends!

🔬 New AGA guidance spotlights 💡 advanced therapies for moderate-to-severe #CrohnDisease 🚨 ✅ Upfront biologics > step-up 👉 tinyurl.com/ms2yb3p7 #GITwitter #MedTwitter #IBD @AmerGastroAssn @ESGE_news @my_ueg @IBD_JohnD @IBDMD @IbdClub @DCharabaty @IBD_FloMD @IBD_docGio

Post-op surveillance of CD. ➡️Algorithm below from @MRegueiroMD highlighting role for IUS in post-op surveillance ➡️If you're interested in integrating point-of-care IUS post-op, please check out the following visual atlas: pubmed.ncbi.nlm.nih.gov/4133… #aibd2025 @iUSCAN

Congrats to @MichaelKappel12 on his well-deserved #ShermanPrize! 🏆 I’m sad to miss the ceremony, but want to shout out what a generous #mentor he is and what an incredible asset he’s been to all of us in #PedsIBD. 🙌 #AIBD2025 shermanprize.org/news/unc-pe…

Ready for Day2 of #AIBD2025? I’m ready to face the frigid cold rooms and ready to learn from the #IBD experts! As an AIBD Ambassador today, I will be covering the #ComplementaryMedicine Session, 5-6:30pm! See you at the room southern hemisphere II with this incredible panel 👇🏾

At #AIBD2025, we reviewed the European ECCO-ESPGHAN pediatric CD guideline, which recommends exclusive enteral nutrition (EEN) as a first-line option for inducing remission in low-risk luminal Crohn’s. 🥤 EEN offers strong mucosal outcomes but remains socially challenging for many families, and this approach does not necessarily reflect current U.S. practice. A U.S. pediatric CD guideline is in development. pubmed.ncbi.nlm.nih.gov/3302…